Table 2.
Change in standardized uptake values (SUVs) in the MBP, liver, and lesions during R-CHOP therapy in study patients (n = 60)
| Baseline PET | Interim PET | Final PET | p value a | |
|---|---|---|---|---|
| MBP SUVmax (mean ± SD) | 1.76 ± 0.33 | 1.66 ± 0.30 | 1.75 ± 0.25 | 0.074 |
| MBP SUVmean (mean ± SD) | 1.42 ± 0.27 | 1.32 ± 0.21 | 1.40 ± 0.20 | 0.019 |
| Liver SUVmax (mean ± SD) | 3.00 ± 0.57 | 2.98 ± 0.42 | 3.08 ± 0.45 | 0.340 |
| Liver SUVmean (mean ± SD) | 1.98 ± 0.42 | 1.96 ± 0.30 | 2.04 ± 0.29 | 0.092 |
| Lymphoma lesion FDG uptake | ||||
| MTV, cm3 (mean ± SD) | 278.15 ± 410.92 | 1.16 ± 4.53 | 0.51 ± 2.88 | <0.001 |
| TLG (mean ± SD) | 1934.88 ± 2814.10 | 4.78 ± 20.92 | 2.37 ± 13.85 | <0.001 |
| Bone marrow FDG uptake | ||||
| MTV, cm3 (mean ± SD) | 12.85 ± 30.23 | 63.27 ± 121.45 | 59.05 ± 99.84 | 0.003 |
| TLG (mean ± SD) | 36.45 ± 86.81 | 197.12 ± 422.51 | 177.03 ± 316.27 | 0.002 |
aRepeated measures ANOVA
MTV metabolic tumor volume, TLG total lesion glycolysis